局部晚期食管鳞癌术前同期放化疗疗效及预后因素分析

doi:10.3760/cma.j.cn113030-20191008-00004

Abstract
Figure/Table
References(19)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the therapeutic effects and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Methods The clinical data of a total of 148 patients with locally advanced esophageal squamous cell carcinoma enrolled in the Affiliated Cancer Hospital of Zhengzhou University from 2007 to 2017 were retrospectively analyzed. The patients received 5-Fu/Cisplatin or Paclitaxel/Cisplatin for chemotherapies. The total treatment dose for the radiotherapy was delivered at 36-40Gy under conventional fractionation. Kaplan-Meier method was used to calculate survival rates, and Log-rank test and Cox model were performed for univariate analysis and multivariate analysis, respectively. Results The overall survival (OS) rates of 1-, 3-and 5-year were 74%, 51% and 51%, respectively, with a median survival time (MST) of 72.4 months. The carcinoma/disease-free survival (DFS) rates for 1, 3, 5 years were 60%, 51%, 45%, respectively, with a median time of 60.1 months. The 1-, 3-and 5-year OS rates of the pCR group were 86%, 70%, 70%, the ones of which in the non-pCR group were 70%, 44%, 43%, respectively (P=0.002). The 1-, 3-and 5-year DFS rates were 76%, 71%, 68% for the pCR group, and 53%, 43%, 37% for the non-pCR group, respectively (P=0.002). In pN(-) group and pN(+) group, the 1-, 3-and 5-year OS rates were 83%, 56%, 55% and 50%, 38%, 38%(P=0.004), respectively. Further, the 1-, 3-and 5-year DFS rates were 66%, 56%, 51% for the pN(-) group, and 43%, 38%, 31% for the pN(+) group (P=0.006), respectively. Multivariate analysis revealed that pCR and pN status were independent prognostic factors for OS and DFS (P=0.012, 0.011 and P=0.025, 0.033). Conclusion Neoadjuvant chemoradiotherapy demonstrated significant therapeutic effects in the treatment of locally advanced esophageal squamous cell carcinoma, while pCR and pN status served as independent prognostic factors.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wu Xiaoyuan
	Yang Yuanyuan
	Xing Wenqun
	Li Xue
	He Chunyu
	Jiang Qiong
	Liu Jinsong
	Wang Jianhua

Key words： Esophageal neoplasms/radiotherapy Esophageal neoplasms/chemotherapy Esophageal neoplasms/surgery Prognosis

Received: 08 October 2019

Fund:Fund program:Construction Project of Henan Provincial Department of Medical Science and Technology Projects (201301015)

Corresponding Authors: Wang Jianhua, Email:huajianye@sina.cn

Cite this article:

Wu Xiaoyuan,Yang Yuanyuan,Xing Wenqun et al. Analysis of the therapeutic effects and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(5): 337-341.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20191008-00004 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I5/337

[1] 郑荣寿, 孙可欣, 张思维, 等.2015 年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.005.
Zheng RS, Sun KX, Zhang SW, et al. Analysis of the prevalence of malignant tumors in China in 2015[J]. Chin J Oncol, 2019, 41(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.005.
[2] Herskovic A, Russell W, Liptay M, et al. Esophageal carcinoma advances in treatment results for locally advanced disease[J]. Ann Oncol, 2011, 23(5):1095-1103. DOI:10.1093/annonc/mdr433.
[3] Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J]. Lancet Oncol, 2011, 12(7):681-692. DOI:10.1016/S1470-2045(11)70142-5.
[4] Van Hagen P, Hulshof M, Van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI:10.1056/NEJMoa1112088.
[5] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27):2796. DOI:10.1200/JCO.2018.79.1483.
[6] Shapiro J, Van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1090-1098. DOI:10.1016/S1470-2045(15)00040-6.
[7] 吴小源,邢文群,刘劲松,等. 局部进展期食管鳞癌术前同期放化疗的Ⅱ期临床研究[J]. 中华放射肿瘤学杂志, 2015, 24(1):25-28. DOI:10.3760/cma.j.issn.1004-4221.2015.01.007.
Wu XY, Xing WQ, Liu JS, et al. Clinical study of the Ⅱ stage of radiotherapy and chemotherapy for local progression esophageal squamous cell carcinoma in the same period[J]. Chin J Radiat Oncol, 2015, 24(1):25-28. DOI:10.3760/cma.j.issn.1004-4221.2015.01.007.
[8] Liu SL, Yang H, Zhang P, et al. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma:A matched case-control study[J]. Radiother Oncol, 2015, 116(2):262-268. DOI:10.1016/j.radonc.2015.07.020.
[9] Van Hagen P, Wijnhoven BPL, Nafteux P, et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer[J]. Br J Surg, 2013, 100(2):267-273. DOI:10.1002/bjs.8968.
[10] Tong DKH, Law S, Kwong DLW, et al. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor[J]. Ann Surg Oncol, 2010, 17(8):2184-2192. DOI:10.1245/s10434-010-0995-2.
[11] Scheer RV, Fakiris AJ, Johnstone PAS. Quantifying the Benefit of a Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in the Treatment of Esophageal Cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 80(4):996-1001. DOI:10.1016/j.ijrobp.2010.03.003.
[12] Philippron A, Bollschweiler E, Kunikata A, et al. Prognostic relevance of lymph node regression after neoadjuvant chemoradiation for esophageal cancer[J]. Semin Thorac Cardiovasc Surg, 2016, 28(2):549-558. DOI:10.1053/j.semtcvs.2016.04.003.
[13] Hölscher AH, Drebber U, Schmidt H, et al. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma[J]. Ann Surg, 2014, 260(5):779-785. DOI:10.1097/SLA.0000000000000964.
[14] 谭立君,刘晓,肖泽芬,等.592例食管癌三维放疗的预后分析[J]. 中华放射肿瘤学杂志, 2015, 24(1):10-15. DOI:10.3760/cma.j.issn.1004-4221.2015.01.004.
Tan LJ, Liu X, Xiao ZF, et al. Analysis of outcomes and prognostic factors in 592 esophageal cancer patients treated with three-dimensional radiotherapy[J]. Chin J Radiat Oncol, 2015, 24(1):10-15. DOI:10.3760/cma.j.issn.1004-4221.2015.01.004.
[15] Blackham AUH, Naqvi SM, Schell MJ, et al. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer[J]. J Surg Oncol, 2018, 117(2):150-159. DOI:10.1002/jso.24808.
[16] 吴昌荣,薛恒川,朱宗海,等. 现代二野淋巴结清扫食管癌切除术的疗效分析[J]. 中华肿瘤杂志, 2009, 31(8):630-633. DOI:10.3760/cma.j.issn.0253-3766.2009.08.015.
Wu CR, Xue HC, Zhu ZH, et al. Efficacy analysis of modern wild lymph node dissection and esophageal carcinoma resection[J]. Chin J Oncol, 2009, 31(8):630-633. DOI:10.3760/cma.j.issn.0253-3766.2009.08.015.
[17] Ma J, Zhan C, Wang L, et al. The sweet approach is still worthwhile in modern esophagectomy[J]. Ann Thorac Surg, 2014, 97(5):1728-1733. DOI:10.1016/j.athoracsur.2014.01.034.
[18] Giugliano DN, Berger AC, Pucci MJ, et al. Comparative quantitative lymph node assessment in localized esophageal cancer patients after R0 resection with and without neoadjuvant chemoradiation therapy[J]. J Gastrointest Surg, 2017, 21(9):1377-1384. DOI:10.1007/s11605-017-3478-y.
[19] Talsma AK, Shapiro J, Looman CWN, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy:prognostic and therapeutic impact on survival[J]. Ann Surg, 2014, 260(5):786-793. DOI:10.1097/SLA.0000000000000965.